Target type: biologicalprocess
Any process that stops, prevents or reduces the frequency, rate or extent of execution phase of apoptosis. [GOC:mtg_apoptosis, GOC:TermGenie]
Negative regulation of execution phase of apoptosis refers to the cellular processes that actively prevent or inhibit the final stages of programmed cell death, also known as apoptosis. This intricate regulatory mechanism is crucial for maintaining tissue homeostasis and preventing uncontrolled cell death. Here's a breakdown of the key aspects:
**1. Activation of Apoptosis:**
- Apoptosis is initiated by intrinsic (internal) or extrinsic (external) pathways.
- Intrinsic pathway involves cellular stress, DNA damage, and mitochondrial dysfunction, ultimately leading to the release of cytochrome c from mitochondria.
- Extrinsic pathway involves death receptor activation, such as TNFα, Fas, or TRAIL, triggering caspase cascades.
**2. Execution Phase of Apoptosis:**
- This phase involves the activation of executioner caspases (caspase-3, -6, and -7), which cleave specific target proteins within the cell.
- These cleavages lead to characteristic apoptotic features, such as DNA fragmentation, cell shrinkage, and formation of apoptotic bodies.
**3. Negative Regulation Mechanisms:**
- **Inhibition of Caspase Activation:**
- **Caspase Inhibitors:** Proteins like IAPs (inhibitor of apoptosis proteins) bind to and inhibit activated caspases, preventing their proteolytic activity.
- **Apoptosis-Inducing Factor (AIF):** This protein, released from mitochondria, can interact with IAPs and promote their degradation, thereby indirectly activating caspases.
- **Regulation of Mitochondrial Integrity:**
- **Anti-Apoptotic Bcl-2 Family Members:** Proteins like Bcl-2, Bcl-xL, and Mcl-1 bind to pro-apoptotic Bcl-2 family members (e.g., Bax and Bak) and block their ability to permeabilize the mitochondrial membrane. This prevents the release of cytochrome c and other apoptogenic factors.
- **Mitochondrial Membrane Potential Maintenance:** Processes that ensure mitochondrial integrity, such as ATP production and reactive oxygen species (ROS) scavenging, contribute to preventing mitochondrial membrane permeabilization and subsequent apoptosis.
- **Signal Transduction Pathways:**
- **Survival Signaling:** Activation of pathways involving PI3K/Akt and NF-κB promotes cell survival by inhibiting pro-apoptotic signals and enhancing anti-apoptotic mechanisms.
- **Autophagy:** This cellular process, often triggered by nutrient deprivation or stress, can act as a survival mechanism by degrading damaged components and providing energy. In some cases, autophagy can also contribute to apoptosis.
**4. Importance of Negative Regulation:**
- **Tissue Homeostasis:** Preventing excessive apoptosis is crucial for maintaining tissue integrity and function.
- **Immune System Regulation:** Proper negative regulation of apoptosis is essential for controlling immune responses and preventing autoimmune disorders.
- **Developmental Processes:** Apoptosis plays a role in development, and its regulation ensures proper tissue formation and removal of unwanted cells.
- **Cancer:** Dysregulation of apoptosis pathways can contribute to the development and progression of cancer.
**Note:** Negative regulation of apoptosis is a complex process involving numerous pathways and interacting components. It is tightly controlled to ensure appropriate responses to various cellular stimuli.'
"
Protein | Definition | Taxonomy |
---|---|---|
Bcl-2-like protein 1 | A Bcl-2-like protein 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q07817] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
oxamic acid | oxamic acid : A dicarboxylic acid monoamide resulting from the formal condensation of one of the carboxy groups of oxalic acid with ammonia. Oxamic Acid: Amino-substituted glyoxylic acid derivative. | dicarboxylic acid monoamide | Escherichia coli metabolite |
hoe 33342 | BXI-72: structure in first source | bibenzimidazole; N-methylpiperazine | fluorochrome |
chelerythrine | chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae. | benzophenanthridine alkaloid; organic cation | antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor |
chlorcyclizine | chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness | diarylmethane | |
gossypol | Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer. | ||
sanguinarine | benzophenanthridine alkaloid : A specific group of isoquinoline alkaloids that occur only in higher plants and are constituents mainly of the Papaveraceae family. | alkaloid antibiotic; benzophenanthridine alkaloid; botanical anti-fungal agent | |
2-phenylphenol | 2-phenylphenol: RN given refers to parent cpd; structure biphenyl-2-ol : A member of the class of hydroxybiphenyls that is biphenyl substituted by a hydroxy group at position 2. It is generally used as a post-harvest fungicide for citrus fruits. | hydroxybiphenyls | antifungal agrochemical; environmental food contaminant |
4-phenylphenol | 4-phenylphenol: RN given refers to cpd without isomeric designation biphenyl-4-ol : A member of the class of hydroxybiphenyls that is biphenyl carrying a hydroxy group at position 4. | hydroxybiphenyls | |
paclitaxel | Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL). | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent |
epigallocatechin gallate | (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin. epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis) | flavans; gallate ester; polyphenol | antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite |
5,6,7,8-tetrahydro-1-naphthol | 5,6,7,8-tetrahydro-1-naphthol : 1-naphthol hydrogenated at C-5, -6, -7 and -8. | tetralins | |
benzo(b)thiophene-2-carboxylic acid | benzo(b)thiophene-2-carboxylic acid: for prevention of osteoporosis; structure given in first source | ||
alexidine dihydrchloride | |||
6-n-tridecylsalicylic acid | 6-n-tridecylsalicylic acid: structure given in first source | hydroxybenzoic acid | |
resveratrol | trans-resveratrol : A resveratrol in which the double bond has E configuration. | resveratrol | antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger |
apogossypol | apogossypol: structure in first source | ||
umi-77 | UMI-77: an Mcl-1 inhibitor; structure in first source | ||
thioguanine anhydrous | Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia. | 2-aminopurines | anticoronaviral agent; antimetabolite; antineoplastic agent |
5,6-dehydrokawain | 5,6-dehydrokawain: from Alpinia speciosa rhizoma; RN given for cpd without isomeric designation; structure given in first source | 2-pyranones; aromatic ether | |
kendomycin | kendomycin: structure in first source | benzofurans | |
rehmannic acid | rehmannic acid: toxic principle, triterpene acid from Lantana camara; RN given refers to (22beta-(Z))-isomer; structure | ||
abt-737 | aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound | anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor | |
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide | benzamides | ||
MI-63 | MI-63 : An azaspiro compound resulting from the formal fusion of position 3 of 6-chloro-oxindole with position 3 of (2R,3SS5S)-3-(3-chloro-2-fluorophenyl)-5-(2,2-dimethylpropyl)-N-[2-(morpholin-4-yl)ethyl]pyrrolidine-2-carboxamide. It is a potent inhibitor of the MDM2-p53 interaction. | azaspiro compound; monochlorobenzenes; monofluorobenzenes; morpholines; oxindoles; pyrrolidines; secondary carboxamide | apoptosis inducer |
marinopyrrole a | (-)-marinopyrrole A : A member of the class of pyrroles that is 1'H-1,3'-bipyrrole substituted by four chloro groups at positions 4, 4', 5 and 5' and two 2-hydroxybenzoyl moieties at positions 2 and 2'. It is isolated from Streptomyces sp.CNQ-418 and exhibits cytotoxic and antibacterial activities. marinopyrrole A: antibiotic from a marine Streptomyces sp.; structure in first source | aromatic ketone; organochlorine compound; phenols; pyrroles | antibacterial agent; antimicrobial agent; antineoplastic agent; bacterial metabolite; marine metabolite |
navitoclax | aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound | antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor | |
ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4h-chromene-3-carboxylate | ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: has antineoplastic activity; structure in first source | ||
meiogynin a | meiogynin A: from the bark of Meiogyne cylindrocarpa; structure in first source | ||
abt-199 | venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion. venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source. | aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine | antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor |
jy-1-106 | JY-1-106: a BH3 alpha-helix mimetic that functions as a pan-Bcl-2 inhibitor; structure in first source | ||
a-1155463 | A-1155463: a Bcl-X(L) inhibitor; structure in first source | ||
bm-1197 | BM-1197: inhibits both Bcl-xL and Bcl-2; has antineoplastic activity | ||
a-1331852 | A-1331852: a Bcl-X(L) inhibitor; structure in first source | ||
BDA-366 | BDA-366 : A member of the class of anthraquinone that is 1,4-diamino-9,10-anthraquinone in which the two amino groups are carrying 3-(diethylamino)-2-hydroxypropyl and (oxiran-2-yl)methyl substituents. It exhibits anti-cancer properties. BDA-366: has antineoplastic activity; binds Bcl-2 protein; structure in first source | anthraquinone; epoxide; secondary alcohol; secondary amino compound; tertiary amino compound | antineoplastic agent; apoptosis inducer |
apogossypolone | apogossypolone: has antineoplastic activity; structure in first source |